CORT director exercises 2,200 options, sells shares at $87.54
Corcept Therapeutics (CORT) director reports option exercise and sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 2,200 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,200 | $14.08 | $31K |
| Sale | Common Stock | 2,200 | $87.54 | $193K |
Footnotes (2)
- F1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 1, 2024 in effect at the time of this transaction.
- F2. Fully exercisable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CORT report on Form 4?
Was the CORT insider sale under a 10b5-1 plan?
How many CORT options does the insider still hold?
What is the expiration date of the remaining CORT options?
What were the transaction codes on the CORT Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.